Unlike many biotech companies that focus on developing therapeutic proteins and peptides or have a platform technology, AnorMED uses chemistry as its backbone to discover and develop new drugs.

AnorMED Inc. was established by a team of seven scientists, led by Michael Abrams, most of whom worked together from 1985 as integral members of the biomedical research group of Johnson Matthey plc (JM), U.K.

AnorMed's key products are AMD3100, a stem cell mobilizer and AMD070 which the Company's lead HIV candidate being conducted in collaboration with the Adult AIDS Clinical Trials Group. In the area of HIV, AnorMED has also developed a series of compounds that inhibit the CCR5 receptor, and plans to select a lead candidate for clinical studies. The Company also has a preclinical program evaluating the potential of CXCR4 inhibitors in oncology.